Fosun Pharma Unit Secures Exclusive Rights to Advanced Bispecific Antibody Drug
Shanghai Fosun Pharma files HKEX next-day return disclosing H-share buyback at HKD 16.53
Fosun Pharma 1H FY26 profit attributable to shareholders rises 19.09% to RMB 1.14 billion; revenue increases 4.75% to RMB 20.44 billion
Regent Pacific returns to profit in H1 FY26, net profit US$544,000
Fosun Pharma unit starts China Phase II trial of COPD drug candidate FXS7553
Fosun Pharma Subsidiary Wins Approval for Pediatric Constipation Drug in China